Skip to main content

Diabetic Macular Edema Market Expected to Expand at a Steady CAGR through 2027

Press Release   •   Jan 24, 2017 01:35 EST

Diabetic Macular Edema Market Share

Macular edema is condition in diabetes patient’s that results in a retinal thickening within 2 disc diameter of the center of the macula. This results from changes in retinal microvascular that compromise the blood retinal barrier and cause leakage of plasma in the surrounding retina causing retinal edema. Due to the leakage in blood vessels fluid is accumulated in part of retina that controls most of the vision. Diabetic Macular Edema (DME) is caused in patients with diabetic retinopathy. Diabetic retinopathy is disease that damages the normal functioning of blood vessels in retina. The untreated blood vessels begins to create pressure in the eyes and leakage in eye. DME and diabetes retinopathy is common problems faced by diabetic patients. As per the report of American Diabetes Association in 2012, 29.1 million of Americans were diagnosed diabetic that contributes 9.3% of population have diabetes. In 2005-2008, in U.S. adults with diabetes aged 40 years and older, 4.2 million were diagnosed with diabetic retinopathy. As per a research published in 2013 reported 2.6% of global blindness is caused by diabetes condition. As per the report of WHO in 2016, the number of prevalent cases of diabetes has risen from 108 million in 1980 to 422 million in 2014 and is expected to be rising faster in middle and low income countries. There are two kind of DME based on the mechanism of in which fluid enters macula: Focal DME is caused due to abnormalities in blood vessels, which is also known as microaneurysms. Diffuse DME is caused by the widening or swelling of retinal capillaries. The treatment for focal and diffuse DME differ but both involves treatment with laser procedure. Focal DME is mostly treated with focal laser and diffuse DME is treated with grid laser treatment. Both the treatment processes involves treating the leakage in the macula. Chronic inflammation is also expected to promote vascular dysfunction and occlusion. The consequences of vascular dysfunction includes hypoxia. In response to local hypoxia affected tissues increases the production of growth factors such as vascular endothelial growth factor (VEGF). The ideal treatment for diabetic macular edema includes primary prevention.

Diabetic Macular Edema Market: Drivers and Restraints

The global diabetic macular edema market is expected to be fueled by the advancement ophthalmic surgery techniques. The key drivers of the market are the increasing cases of diabetic retinopathy and DME, the growing ageing population, family history of diabetes and the changing lifestyle. The increasing government initiatives to diagnosis and treatment of diabetes and the diseases caused by diabetes is also expected to fuel diabetic macular edema market. The lack of awareness, less experienced professionals, lack of reimbursement and increasing cases associated with failure of diabetic macular edema surgery is expected to hinder the growth of the market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2697

Diabetic Macular Edema Market: Segmentation

The diabetic macular edema Market is classified on the basis of indication, treatment, end user and geography.

Based on indication type, the global diabetic macular edema market is segmented into the following:

  • Focal DME
  • Diffuse DME

Based on treatment type, the global diabetic macular edema market is segmented into the following:

  • Focal Laser treatment
  • Grid Laser treatment
  • Anti-VEGF therapy
  • Corticosteroid Therapy
  • Implants

Based on end user, the global Diabetic Macular Edema Market is segmented into the following:

  • Hospitals
  • Ambulatory Surgical Centers
  • Ophthalmic Clinics

Diabetic Macular Edema Market: Overview

The ongoing advancement in the ophthalmic surgery technique is expected to drive the market of diabetic macular edema. The increasing awareness among the practitioners of using the laser therapy is showing a significant growth towards global diabetic macular edema market. The recent U.S FDA approval to Bausch & Lomb, fluocinolone acetonide intravitreal implant has increased the growth of this market. This type of treatment is expect to be a great help in the management of DME. This implant is approved for the treatment of chronic noninfectious posterior uveitis. The Hospital end user segment is expected to have maximum share in the market and is also expected to remain in with the maximum share.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2697

Diabetic Macular Edema Market: Regional Overview

Region wise, the global diabetic macular edemamarket is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global market for diabetic macular edema due to better experts, better reimbursement and awareness among the common people followed by Europe. The growing adoption of these device by the ophthalmic surgeons in APEJ is also expected to drive the market.

Market: Key Players

Some of the key players in global diabetic macular edemamarket Genentech USA, Inc Eyetech Pharmaceuticals, Bausch & Lomb, Alimera Sciences, Allergan, SurModics, Inc. and others.

Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.

Contact

3rd Floor,
207 Regent Street,
London - W1B 3HH
United Kingdom
T: + 44 (0) 20 7692 8790
D: +44 (0) 20 3287 4268
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

Comments (0)

Add comment

Comment